United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.3 mg - menest is indicated in the: menest should not be used in women with any of the following conditions:

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.3 mg - tablet, film coated - excipient ingredients: sucrose; hyprolose; macrogol 400; carnauba wax; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; polysorbate 80; quinoline yellow aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1. premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 1.25 milligram - natural and semisynthetic estrogens, plain

Australia - English - Department of Health (Therapeutic Goods Administration)

revvity pty ltd - ct852 - estrogen (oestrogen) ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of estrogen (oestrogen) hormones in a clinical specimen.

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - estrogen 9x, 12x, 30x, 60x - for the temporary relief of occasional headache, diarrhea, cramps, coughing, sneezing, or runny nose due to sensitivity to phenolic compounds found in foods or other products.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - tablets modified release - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene - treatment of the following conditions in women with a uterus:• treatment of moderate to severe vasomotor symptoms associated with menopause• prevention of postmenopausal osteoporosis

Canada - English - Health Canada

wyeth canada - conjugated estrogens - tablet - 0.9mg - conjugated estrogens 0.9mg - estrogens

Canada - English - Health Canada

pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 2.5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 2.5mg - estrogens